CPI-200

**CPI-200** is an investigational intravenous antineoplastic nanomedicine developed using Coordination Pharmaceuticals' nanoscale coordination polymer platform. Public disclosures describe it as a nanoscale coordination polymer containing two undisclosed new molecular entities intended to produce synergistic antitumor activity. It was evaluated as monotherapy in a first-in-human dose-escalation study in patients with advanced solid tumors. ([prnewswire.com](https://www.prnewswire.com/news-releases/coordination-pharmaceuticals-announces-enrollment-of-the-first-patient-in-phase-1-study-of-cpi-200-in-patients-with-advanced-tumors-300899038.html))

Other names

CPI200CPI-200CPI 200